On Wednesday, March 25, the National Coalition on Health Care distributed a memo to summarize the provisions included in the 500+ pages of legislative text of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, H.R. 748. […]
As part of its mission to bring together stakeholders to achieve an affordable, high-value health system, NCHC advocates for constructive policy change. While some members of NCHC do not, or cannot, take positions either on specific legislation, strategies, or on any policies outside their respective mission areas, all that can, do endorse broad policy positions in support of comprehensive health system change. Here is the policy correspondence sent from the National Coalition on Health Care.
Here, you will find all of NCHC's policy correspondence from 2017-present. Please see here for all 2016 and previous policy correspondence.
On March 19, 2020, the National Coalition on Health Care (NCHC) sent a letter to Congress with policy recommendations that amplify the short- and long-term needs of those affected most by COVID-19. […]
We recently expressed cautious support for the CMMI Geographic Direct Provider Contracting model in a letter to CMS. New opportunities for physician groups, health plans, and other organizations to partner to serve Medicare, and Medicare and Medicaid dual-eligible beneficiaries could bring new innovations in care delivery to more beneficiaries. As the number of alternative payment […]
Enough is enough–it is time for Congress to address rising insulin prices. Congress has failed to take any action to address the rising cost of insulin. However, the Protecting Access to Biosimilars Act of 2019, introduced by Rep. Diana DeGette (D-CO) in early April, is a promising first step to address the issue. The Energy […]
On April 10th, NCHC President & CEO John Rother presented at the World Orphan Drug Congress 2019 Conference & Expo to discuss potential policy options to address the rising cost of drugs. Mr. Rother discussed proposals from the FDA, HHS, and Congress. Mr. Rother also identified 4 feasible options to address drug affordability. The slides […]